Ludwig Cancer Research is an international community of distinguished scientists dedicated to preventing and controlling cancer. American businessman Daniel K. Ludwig began to support cancer research with the establishment of the Ludwig Institute for Cancer Research in 1971. Today, the scientific efforts endowed through his resources have grown to encompass the Ludwig Institute and the Ludwig Centers and professorships at six U.S. institutions.

Leadership

Board of Directors

A Board of Directors has the ultimate responsibility for the Ludwig Institute for Cancer Research and the Ludwig Fund. Although they are separate Boards, the members are the same. Several board members also served as trustees of the Virginia and D.K. Ludwig Fund for Cancer Research, which oversaw the endowment of the six Ludwig Centers in the United States.

John L. Notter
Chair of the Board; Board Member, Conrad N. Hilton Foundation
Nancy E. Davidson, MD
Fred Hutchinson Cancer Research Center
Olivier Dunant
Law firm of Borel & Barbey
John D. Gordan III
Law firm of Morgan, Lewis & Bockius (retired)
Alexandra Johnson
Law firm of Bär & Karrer
Barbara S. Jones
Law firm of Bracewell LLP
Philip A. Pizzo, MD
Stanford University School of Medicine
Edward A. McDermott Jr.
President and Chief Executive Officer
Chi Van Dang, MD, PhD
Scientific Director
Scientific Advisory Committee

The Scientific Advisory Committee is a group of distinguished independent scientists and clinicians appointed by the Scientific Director of the Ludwig Institute to advise on emerging areas of cancer research and development that might help the Institute fulfill its mission. The group also assists in the scholarly review of Institute scientists.

History

Daniel K. Ludwig was born June 24, 1897, in South Haven, Michigan, USA. By the 1960s he was among the richest men in the world, with a self-made empire of some 200 companies. By the time of his death, he had pioneered the modern supertanker, participated in major oil and gas projects throughout the world, become a major investor and operator in the production of coal and other minerals, acquired and developed luxury hotels and other real estates, and developed a forest-products and agricultural enterprise that encompassed three million acres in the Amazon basin.

In 1971, he launched the Ludwig Institute for Cancer Research (he had to be persuaded strongly to allow his name to be used), endowing it with nearly all of his international holdings. That endowment is managed by the LICR Fund.

Upon his death in August 1992, Mr. Ludwig’s estate also provided for cancer research support at six leading U.S. academic institutions.

READ DANIEL LUDWIG’S FOUNDING STATEMENT

How we’re organized

The Ludwig Institute for Cancer Research Ltd is an international not-for-profit organization with a legacy of pioneering cancer discoveries that spans more than 45 years. The Institute provides its scientists with the resources and the flexibility to realize the life-changing potential of their work and see their discoveries advance human health. This philosophy, combined with robust translational programs, maximizes the potential of breakthrough discoveries to be more attractive for commercial development.

The Ludwig Institute conducts its own research and clinical trials, bridging the most basic questions of life to the most pressing needs of cancer care. Since its inception, the Institute has invested more than $1.8 billion of its own resources in cancer research, and has an endowment valued at $1.5 billion.

In addition, Ludwig Centers and Ludwig professorships have been established at six leading U.S. institutions. The Centers, created in 2006, operate independently of the Ludwig Institute but work collaboratively with each other and with the Institute at the forefront of cancer research. Each Center has a secure level of funding that generates more than $2 million a year in perpetuity. This funding empowers the Centers to attract the best and brightest scientists and provides unconstrained resources to tackle the most challenging projects for the benefit of cancer patients.

Funding

The LICR Fund

The LICR Fund Inc. is a US 501(c)3 organization that manages the assets of the Ludwig Institute for Cancer Research.

The LICR Fund’s investment goal is to provide sustainable core spending for the Ludwig Institute while maintaining the purchasing power of the Fund for future generations of scientists. The Fund, valued currently at $1.5 billion, is overseen by a Board of Directors, which determines investment policy and objectives, defines guidelines for the allocation of assets and—together with the Institute’s Investment Office—appoints and evaluates outside investment managers.

The Fund’s orientation is global and broadly diversified, with an investment portfolio incorporating a range of asset classes and strategies designed to achieve its risk-adjusted objectives.

The Virginia and D.K. Ludwig Fund

The Virginia and D.K. Ludwig Fund for Cancer Research endowed the Ludwig Centers under the terms of the will of Daniel Ludwig. Each Center is endowed, providing generous and secure funding for the indefinite future.

Careers

Ludwig is always hungry for creative scientific minds and brilliant people to help further our mission. Check this space regularly for the latest job openings at our locations around the world.

Postdoctoral scholar at the Ludwig Center at Chicago
Chicago

Postdoctoral scholar at the Ludwig Center at Chicago

The University of Chicago’s Ludwig Center for Metastasis Research in the Department of Radiation and Cellular Oncology is seeking Postdoctoral Scholars to join a diverse and vibrant lab with a long history of breakthrough translational research. Openings currently exist in research teams seeking to better understand and reduce the process of tumor metastasis and improve the anti-tumor action of cancer therapies. Several key collaborations are driving our lab’s current focus: through our ongoing collaboration with Dr. Yang-Xin Fu we continue to investigate core pathways and mechanisms underlying immune responses in the context of radiotherapy and immunotherapy; Dr. Chuan He has been working with us recently to elucidate the effects of modification of m6A methylation on the anti-tumor action of radiotherapy and immunotherapy; and we are partnering with Dr. Wenbin Lin to develop immuno-nanomedicine approaches that can be employed with radiotherapy. Recent publications from these collaborative investigations include Yang et al. J Exp Med 2021, Hou et al. Sci Transl Med 2021, Zheng et al. Cancer Res 2020, Shi et al. J Exp Med 2020, Ni et al. Sci Adv 2020, Arina et al. Nat Commun 2019, Chan et al. Biomaterials 2019, Han et al. Nature 2019, Hou et al. Immunity 2018, Liang et al. Nat Commun 2017; Xu et al. Immunity 2017; Deng et al. J Clin Invest 2014, and Deng et al. Immunity 2014. Additional opportunities to consult and/or participate in the composition and execution of translational research grant applications and design and implementation of clinical trials related to immunology and radiotherapy are also available. Qualified applicants must possess a doctorate degree. Ideal candidates would possess a strong background in radiation biology or immunology, with experience in tumor biology and/or tumor immunology, standard immunology techniques/assays, adoptive Tcell therapy, molecular biology, animal models of human cancer, and bioinformatic analysis. Successful Postdoctoral Scholars in our lab independently drive and conduct their research, with guidance and input from the rest of the group, and therefore they must work well in a team environment. The level of the position and compensation are dependent upon qualifications and experience. We are looking for candidates from a diversity of backgrounds; indeed, over the past five years, Postdoctoral Scholars and Fellows in the Weichselbaum Lab have hailed from seven countries. Interested candidates should submit curriculum vitae, bibliography, a statement of research interests, and contact information for at least three references to Dr. R. Weichselbaum, Dept. of Radiation and Cellular Oncology, 5758 S. Maryland Ave, MC9006, Chicago, IL 60637 USA, or via email to: dcorrea@radonc.uchicago.edu

The University of Chicago is an Affirmative Action/Equal Opportunity/Disabled/Veterans Employer and does not discriminate on the basis of race, color, religion, sex, sexual orientation, gender identity, national or ethnic origin, age, status as an individual with a disability, protected veteran status, genetic information, or other protected classes under the law (including Title IX of the Education Amendments of 1972). For additional information please see the University’s Notice of Nondiscrimination at http://www.uchicago.edu/about/non_discrimination_statement/. Job seekers in need of a reasonable accommodation to complete the application process should call 773-702-0287 or email ACOppAdministrator@uchicago.edu with their request.

Go To Chicago Page    

See Full Job Posting    

Senior Postdoctoral Researcher – Tumour suppression lab at Ludwig Oxford
Oxford

Senior Postdoctoral Researcher – Tumour suppression lab

Grade 8: £41,526 – £49,553 per annum (with discretionary range to £54,131)

We are seeking a highly-motivated and experienced Senior Postdoctoral Researcher to work on a research programme aligned to the core interests of Professor Xin Lu’s laboratory in molecular mechanisms of tumour suppression and cellular plasticity. This is an exciting opportunity to take on wider responsibilities and expand your experience of management and supervision.

You will oversee the day to day operational management of Professor Xin Lu’s laboratory at the Old Road Campus Research Building. You will mentor Ludwig wet-lab students and contribute to their supervision along with Professor Xin Lu, actively providing them with guidance and advice as well as hands-on training in the lab. Ensuring the smooth running of the lab in her absence and that the lab continues to meet its strategic aims, you will manage budgets for the lab and will ensure that staff and students are using funds effectively and overseeing purchases.

It is essential that you hold a relevant PhD / DPhil with significant post qualification research experience. You will have a strong publication record, and familiarity with the field, and possess sufficient specialist knowledge of tumour suppression to develop research project and methodologies. You will have experience in supervising staff and/or students and have excellent communications skills.

Applications for this vacancy are to be made online and you will be required to upload a supporting statement and CV as part of your online application.  Your supporting statement must explain how you meet each of the selection criteria for the post using examples of your skills and experience.

This position is offered full time on a fixed term contract for 3 years and is funded by the Department.

Applications must be made online by 12.00 noon (UK time) on Monday 26 July 2021.

Go To Oxford Page    

See Full Job Posting    

Application for Ludwig Princeton Scholar
Princeton

Princeton University is pleased to announce a search for Ludwig Princeton Scholars, a new program aimed at attracting talented early-career scientists (0-2 years from PhD, MD, or clinical training). The program centers on cancer metabolism, broadly defined to include technology development, computation, biological studies, drug development, and clinical trials relevant to diet, metabolism, cancer, cell growth, metastasis, autophagy, microbiome, and/or the immune system. Scholars will be housed at the new Ludwig Princeton Branch on Princeton University’s campus, or in collaborating labs at the Cancer Institute of New Jersey. Appropriate backgrounds include a Ph.D. in biology, chemistry, computer science, engineering, physics or an M.D. Appointment will be as Associate Research Scholar, renewable for up to five years, with a competitive salary and research support.

Scholars will be given a substantial degree of independence, with mentorship from at least 2 faculty members, one of whom must be a full member of the Ludwig Princeton Branch (currently, these are Yibin Kang, Josh Rabinowitz, and Eileen White).

Scholars may have the opportunity to perform a modest amount of teaching, according to a plan they may develop in conjunction with their mentors. While teaching, a Scholar may hold a secondary appointment as a Lecturer in an appropriate department, pending sufficient course enrollments and the approval of the Dean of the Faculty.

Submission of all application materials is highly encouraged by September 1, 2021. Scholars will be appointed on a rolling basis. Please feel free to contact Panina Zaurov (pzaurov@princeton.edu) with any inquiries about the Ludwig Princeton Scholars Program. To apply online, please visit https://www.princeton.edu/acad-positions/position/20701 and submit a cover letter, curriculum vitae which includes a list of publications, a brief statement (1-2 pages) of research interests and goals, and contact information for three references.

These positions are subject to the University’s background check policy.

Go To Princeton Page    

See Full Job Posting    

Application for Ludwig Postdoctoral Research Associate – Princeton
Princeton

Postdoctoral or more senior research positions are available in the Ludwig Princeton Branch to study metabolism and tumor-microenvironment interactions during cancer progression. Ludwig Princeton Branch is dedicated to accelerating the study of metabolic phenomena associated with cancer to develop new paradigms for cancer prevention and treatment. Its main research areas include:

– Metabolic interactions between the tumor and the rest of the body, focusing on how the body supports tumor growth and metastasis, and how tumors induce cachexia and other microenvironmental changes.
– Interplay between host metabolism, gut microbiome, and anti-cancer immune response.
– Diet-induced tumor microenvironment changes during cancer progression and metastasis, and dietary strategies for the prevention and treatment of cancer.

We welcome highly motivated candidates who have or expect to have a Ph.D. degree in the fields of molecular cell biology, cancer biology, chemical biology, biochemistry, cancer genomics, genetics, mass spectrometry, physical chemistry, computational and systems analysis.

Appointments are for one year with the possibility of renewal pending satisfactory performance and continued funding.

Applicants must select one or more research mentor/co-mentor from the following Principal Investigators and Ludwig Princeton Branch members.

Kang, Yibin https://molbio.princeton.edu/people/yibin-kang
Major areas of interest include: Cellular plasticity in cancer progression, organ-tropic metastasis niches, metabolic adaptation during cancer metastasis, metastasis genes and development of metastasis therapeutics, mammary gland stem cell and stem cell niches.

Rabinowitz, Joshua https://scholar.princeton.edu/rabinowitz/home
Major areas of interest include: Metabolomics, isotope tracing, metabolic flux analysis, quantitative modeling, mass spectrometry imaging, cancer metabolism, small molecule inhibitor discovery, dietary impact on cancer, metabolism, and the immune system.

White, Eileen https://www.cinj.org/research/eileen-white-phd
Major areas of interest include: Identification of metabolic vulnerabilities in cancer, the role of nutrient scavenging pathways including autophagy in cancer and host metabolism, growth and survival, metabolic control of the anti-tumor immune response, identification of the mechanisms driving cancer cachexia, dietary modulation of tumor growth and treatment response.

To apply online, please visit https://www.princeton.edu/acad-positions/position/20721 and submit a brief statement of research interests, curriculum vitae and a list of three references.

This position is subject to the University’s background check policy.

Go To Princeton Page    

See Full Job Posting    

Contact

Baltimore

Ludwig Center at Johns Hopkins
1650 Orleans Street, Cancer Research Building, Room 590
Baltimore, Maryland, U.S. 21287

T 410 955 8878
F 410 955 0548

Boston Harvard

Ludwig Center at Harvard
450 Brookline Avenue
Boston, Massachusetts, U.S. 02215

T 617 632 3985
F 617 632 3408

Boston MIT

Ludwig Center at MIT
77 Massachusetts Avenue, 76-158
Cambridge, Massachusetts, U.S. 02139

T 617 258 5159
F 617 258 5213

Chicago

Ludwig Center at the University of Chicago
5758 South Maryland Avenue MC 9006
Chicago, Illinois, U.S. 60637

T 773 702 0817
F 773 834 7233

Lausanne

Ludwig Institute for Cancer Research, Lausanne
Agora Research Center
Rue du Bugnon 25A, CH-1005 Lausanne

T (41) 21 545 10 77
F (41) 21 692 59 95

New York HQ

Ludwig Institute for Cancer Research
666 Third Avenue, 28th floor
New York, New York, U.S. 10017

T (212) 450 1500
F (212) 450 1565

New York MSK

Ludwig Center at MSK
1275 York Avenue, Box 212
New York, New York, U.S. 10065

T 646 888 3165
F 646 422 0453

Oxford

Ludwig Institute for Cancer Research, Oxford
Nuffield Department of Clinical Medicine
Old Road Campus Research Building
off Roosevelt Drive, Headington, Oxford, OX3 7DQ, UK

T +44 (0) 1865 617507

Princeton

Ludwig Institute for Cancer Research, Princeton
Princeton University
91 Prospect Avenue, 2nd Floor
Princeton, N.J. 08540

T +1 (609) 258-5954

San Diego

Ludwig Institute for Cancer Research, San Diego
9500 Gilman Drive,
Cellular and Molecular Medicine East Building
La Jolla, California, U.S. 92093-0670

T 858 534 7802
F 858 534 7750

Stanford

Ludwig Center at Stanford
Lokey Stem Cell Research Building
265 Campus Dr., 3rd Floor
Stanford, California, U.S. 94305-5323

T 650 234 0675

Zurich

Ludwig Institute for Cancer Research
Stadelhoferstrasse 22
8001 Zurich, Switzerland

T (41) (0) 44 267 62 62

Baltimore
Boston Harvard
Boston MIT
Chicago
Lausanne
New York HQ
New York MSK
Oxford
Princeton
San Diego
Stanford
Zurich
Founding statement

In creating this organization I have been guided by certain principles which throughout my life I have found to be highly effective. Success in any complex enterprise consists in bringing the best minds to bear on each problem, in providing the best resources possible, and in putting each concept into practice whenever and wherever the opportunities are most favorable. I believe firmly in the value of applying these principles in grappling with tasks as momentous as finding ways to relieve the human suffering caused by cancer.

Why should this undertaking be international? The rare vision and ability needed in the battle against cancer are not limited by frontiers, and the scientists who possess these gifts must be sought wherever they are to be found. Nor does cancer reveal itself in the same guise in every nation, but strikes different populations in different forms. Yet despite the growing necessity for concerted worldwide effort, I find no agency, which has both the truly international scope and the substantial resources, which I deem essential for a comprehensive attack on human cancer.

In my judgment the ultimate conquest of this frightful disease is not yet in sight, and the same view is held by most informed physicians and scientists in bio-medical research. In contrast to those who would yield to undue optimism, and who hope for too much from present programs. I am persuaded that eventual mastery of cancer will come only from intense and unremitting scientific exploration over many decades. This should not be hindered by the changing policies of governments and the vagaries of public interest. Accordingly it is my intention that the Institute shall be so structured as to ensure secure and continuing support for the attainment of its aims. The elimination of cancer will surely rank as one of man’s greatest and uncontroversial achievements. That day may be long delayed. How long we cannot tell. But I do not doubt that it will surely come.

D.K. Ludwig
December 17, 1974

Notice
?

You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?

Continue
Cancel